Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: Evaluation using the sixth edition of the UICC TNM staging system

Acta Oncologica

Volumn 45, Issue 2, 2006, Pages 162-167

  Murakami, Ryuji ^a   Nishimura, Ryuichi ^a   Baba, Yuji ^a   Yumoto, Eiji ^a   Oya, Natsuo ^a   Yamashita, Yasuyuki ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; UFT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LARYNX; LARYNX CARCINOMA; LARYNX CARTILAGE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION RESPONSE; RADIODIAGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GLOTTIS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TEGAFUR;

EID: 33645109683     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500490269     Document Type: Article

References (26)

1. International Union Against Cancer (UICC). TNM classification of malignant tumours. In: Sobin LH, Wittekind Ch, editors., 5th ed New York: Wiley-Liss; 1997.
2. Burke LS, Greven KM, McGuirt WT, et al. Definitive radiotherapy for early glottic carcinoma: Prognostic factors and implications for treatment. Int J Radiat Oncol Biol Phys 1997;38:1001-6.
3. Le QTX, Fu KK, Kroll S, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997;39:115-26.
4. Mendenhall WM, Amdur RJ, Morris CG, et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001;19:4029-36.
5. Al-Sarraf M. Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control 2002;9:387-99.
6. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
7. Kohno N, Kitahara S, Tamura E, et al. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology 2002;63:226-31.
8. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 1997;43:29-37.
9. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18:1458-64.
10. Maguire PD, Meyerson MB, Neal CR, et al. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for stage III and IVa head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 2004;58:698-704.
11. Kumamoto Y, Masuda M, Kuratomi Y, et al. FAR. chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck 2002;24:637-42.
12. Murakami R, Nishimura R, Baba Y, et al. Prognostic factors of glottic carcinomas treated with radiation therapy: Value of the adjacent sign on radiological examinations in the sixth edition of the UICC TNM staging system. Int J Radiat Oncol Biol Phys 2005;61:471-5.
13. International Union Against Cancer (UICC). TNM classification of malignant tumours. In: Sobin LH, Wittekind Ch, editors., 6th ed New York: Wiley-Liss; 2002.
14. Murakami R, Baba Y, Furusawa M, et al. Early glottic squamous cell carcinoma: Predictive value of MR imaging for the rate of 5-year local control with radiation therapy. Acta Radiol 2000;41:38-44.
15. Murakami R, Furusawa M, Baba Y, et al. Dynamic helical CT of T1 and T2 glottic carcinomas; predictive value for local control with radiation therapy. AJNR Am J Neuroradiol 2000;21:1320-6.
16. Ferlito A, Silver CE, Howard DJ, et al. The role of partial laryngeal resection in current management of laryngeal cancer: A collective review. Acta Otolaryngol 2000;120:456-65.
17. Schwachöfer JHM, Crooijmans RPMA, Hoogenhout J, et al. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: Influence of treatment sequence. Int J Radiat Oncol Biol Phys 1991;20:1235-41.
18. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
19. Shirasaka T, Shimamoto Y, Ohshimo H, et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993;32:167-72.
20. Iwase H, Shimada M, Nakamura M, et al. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: Longterm results of a phase II study of UFT/CDDP with radiotherapy. Int J Clin Oncol 2003;8:305-11.
21. Fernandez-Martos C, Aparicio J, Bosch C, et al. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: A phase II multicenter study with 3 years' follow-up. J Clin Oncol 2004;22:3016-22.
22. Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979;70:209-14.
23. Simpson D, Robertson AG, Lamont D. A comparison of radiotherapy and surgery as primary treatment in the management of T3N0M0 glottic tumours. J Laryngol Otol 1993;107:912-5.
24. Mendenhall WM, Parsons JT, Mancuso AA, et al. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. J Clin Oncol 1997;15:2394-402.
25. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-21.
26. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.